Meeting
2013 ASCO Annual Meeting
A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).
Authors
Ryan J. Sullivan
Massachusetts General Hospital Cancer Center, Boston, MA
Nageatte Ibrahim , Donald P. Lawrence , Julie Aldridge , F. Stephen Hodi , Keith Flaherty , Christine Conley , Sarah DeNoble , James Walter Mier , Daniel C. Cho , Michael B. Atkins , David F. McDermott , Ryan J. Sullivan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01078961
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9076)
DOI
10.1200/jco.2013.31.15_suppl.9076
Abstract #
9076
Poster Bd #
48G
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
First Author: Kristen Renee Spencer
Poster
2019 ASCO Annual Meeting
Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.
First Author: Baptiste Louveau
Poster
2017 ASCO Annual Meeting
Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).
First Author: Stergios J. Moschos
Poster
2012 ASCO Annual Meeting
A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.
First Author: Jean-Luc Van Laethem